HITHIUM
9.7.2024 12:43:27 CEST | Business Wire | Press release
Stationary battery manufacturer Hithium has successfully deployed the largest battery energy storage system (BESS) project in Eastern Europe to date, with a capacity of 55MWh. This solar plus storage project was realized completely by EPC company Solarpro, in Razlog, Southwestern Bulgaria, where the project is located.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240709299471/en/
Hithium BESS project in Razlog, Bulgaria (Photo: Business Wire)
The new facility officially went live in early June, with the delivery of Hithium’s 16 energy storage containers, each with a capacity of 3.44MWh, to Solarpro. Solarpro is a leading technological provider of solutions for the generation and storage of energy within whole Europe.
Hithium ∞ Block 3.44MWh container
The Hithium ∞ Block 3.44MWh container is a liquid-cooled battery storage system based on Hithium prismatic LFP BESS cells with a 280Ah capacity and a high cyclic lifetime. It is specially optimized for use in stationary battery storage systems with high standards of safety, reliability, and performance. The system’s low levelized cost of storage (LCOS), combined with excellent thermal management, improves energy throughput by ensuring optimal operating temperature and high energy density. It also integrates with a thermal management system, fire protection system, battery management system (BMS), and more.
As Kelson Li, Hithium Senior Director of Sales of DACH, Northern & Eastern Europe said: "We are honored to partner with Solarpro. By providing comprehensive technical and after-sales support throughout the project lifecycle, we aim to foster local expertise and expand the network in Europe. We believe our collaboration with Solarpro will help to accelerate the renewable energy transition and make a positive impact in the region."
Krasen Mateev, CEO of Solarpro adds: "As strategic partners in this landmark project, we are excited to collaborate with Hithium in bringing this significant BESS utility to operation. This undertaking reflects Solarpro’s dedication to advance renewable energy infrastructure in Eastern Europe, ensuring a sustainable energy future for generations to come."
Hithium’s Commitment to the European Market
Hithium is committed to fostering a stronger and more collaborative relationship within the local European market. To this end, the company has set up a regional office in Munich, Germany, offering local support and services. Furthermore, Hithium has formed strategic alliances with other industry leaders, including Scan Global Logistics, to offer unparalleled transportation services, and CarbonX, to advance the energy sector in terms of environmental responsibility and technological advancement.
About Hithium
Hithium is a leading manufacturer of top-quality stationary energy storage products for utility-scale as well as commercial and industrial applications. With more than 20GWh BESS projects shipment up to date. Hithium took the top 5 global market shares and was ranked as the Tier 1 BESS supplier. With four distinct R&D centers and multiple “intelligent” production facilities, Hithium’s innovations include groundbreaking safety improvements to its lithium-ion batteries as well as increases in lifecycle. With decades of cumulative experience in the field among its founders and senior executives, Hithium leverages its specialization in BESS to deliver partners and customers unique advances in energy storage. The company is headquartered in Xiamen, China, with locations in Shenzhen, Chongqing, Munich, Dubai, New York and California.
About Solarpro
Solarpro is a multi-technology integrator with expertise in hybrid projects that include photovoltaic (PV), wind, battery energy storage systems (BESS), and hydrogen solutions. As a leading EPC contractor with 15 years of experience and a team of over 1,000 professionals, Solarpro has designed, built, and integrated PV plants with a total capacity exceeding 7 GW. The company is a technological innovator, excelling in engineering and digitalizing renewable projects, transforming them into dispatchable and flexible assets aligned with energy market developments. Committed to sustainability, Solarpro has further developed expertise in recycling PV modules and batteries to utilize damaged or polluted land, transforming them into state-of-the-art clean energy plants.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709299471/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom